ON Helix is a new translational research conference for the life science industry and academia which takes place on 9 July 2013 at the Wellcome Trust Genome Campus, Cambridge. ABPI members will receive a 10% discount on registration.
This one-day event aims to inform delegates of how to turn early stage inventions and ideas into innovative health treatments. It will present the UK landscape of the business environment, funding, scientific and clinical research excellence and will be a unique knowledge-sharing environment between academia and business. It will combine three main areas:
Keynote presentations from speakers such as Sir William Castell, Chair of the Wellcome Trust; Sir Mike Rawlins, former Chair of NICE and Andy McMenemy, who took the British media by storm in 2011 when he ran 66 ultra marathons in 66 consecutive days in 66 cities of the UK.
Game changing technologies panel – Including a review of the evolution of fundamental technologies like Genomics and Structural Biology and their inputs to translational research from speakers including Professor Mike Stratton, Director of the Wellcome Trust Sanger Institute, and Professor Laurence Pearl, Professor of Structural Biology at the University of Sussex.
Case studies – From companies and collaborative research centres including F-Star, Discuva, MedImmune, Cancer Research UK, Imanova, and GSK who will share their experience of translational research projects.
‘Enabling translational research in the UK’ – A panel which will showcase the UK translational research environment and provide practical advice. Chaired by Mark Treherne, CEO of the UK Life Science Investment Organisation. The panel will include profiling of the activities, support offered by and interests of the Biomedical Catalyst Fund, NOCRI, AHSN, and others.
For more information and to register, please visit: onhelix.com.